Latest Articles

Navigating the Hidden Burden: The Critical Role of Moderate Exacerbations in COPD

Exacerbations are key events in COPD¹ that play a crucial role in disease progression. Although often managed in outpatient settings, exacerbations contribute significantly to the overall burden of COPD.² These events are characterized by an acute worsening of respiratory symptoms, including increased dyspnea associated with cough and production of purulent sputum, increased wheezing and chest discomfort.^1,3 These characteristics reflect an underlying inflammatory response² that exacerbates the disease process.

A video series on round table discussions featuring experts: Biomarkers to guide COPD management

The article "Biomarkers to guide COPD management" features insights from a round table discussion involving leading respiratory experts. It focuses on chronic obstructive pulmonary disease (COPD), a heterogeneous and progressive condition. The experts discuss the risk factors for frequent exacerbation, use of blood eosinophil count (EOS) as a biomarker in COPD, and the association of EOS with type 2 inflammation.

Understanding the Changes in the GOLD Report from 2024 to 2025

The GOLD guidelines provide evidence-based strategies for the diagnosis and management of COPD. The GOLD 2025 update has refined the sections on diagnosis and management of COPD and reflects on the latest evidence on newly recommended therapies.

A review of the clinical implications of eosinophil stability and predictive capability in COPD

This article highlights the stability and predictive value of blood eosinophil levels in COPD, showing their strong link to exacerbation risk. Consistently elevated eosinophil levels can guide personalized treatment, including early use of inhaled corticosteroids (ICS). Integrating eosinophil measurements into routine practice can improve long-term disease management and patient outcomes.

GOLD Recommendations for Treatment and Management of COPD

Unveiling the Secrets to Optimal COPD Management: The GOLD Report Unraveled Imagine having a comprehensive guide that empowers you to take control of your COPD journey. The GOLD report, a beacon of knowledge, offers invaluable insights into diagnosing, managing, and treating this debilitating condition. This report leaves no stone unturned from tailored pharmacological therapies to groundbreaking non-pharmacological strategies. Discover how the GOLD ABE assessment tool, incorporating symptom evaluation and exacerbation risk, paves the way for personalized treatment plans. Unlock the power of eosinophil counts, a game-changer in predicting treatment responses, and embark on a transformative path toward better respiratory health.

An Overview of the impact of Type 2 Inflammation in COPD: Insights from Dr. Surya Bhatt

Chronic Obstructive Pulmonary Disease (COPD) remains a significant health challenge worldwide, characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities. Traditionally, COPD has been associated with neutrophil-driven inflammation, but recent insights suggest a more complex picture, involving Type 2 inflammation in a subset of patients. Dr. Surya Bhatt, a renowned COPD researcher and professor of medicine at the University of Alabama at Birmingham, provides valuable insights into this emerging area of COPD research.

Decoding Type 2 Inflammation in COPD: An Expert’s Perspective

Understanding type 2 inflammation is the key to managing symptoms and exacerbations of COPD.  

The Impact of Exacerbations in COPD

Role of type 2 Inflammation